BCL2 and acute promyelocytic leukemia: In future studies, it would be interesting to investigate BCL2 expression on high-risk primary samples resistant to drug treatment with an ATRA/ATO regimen to delve into the dependencies of clinical APL on the pro-survival BCL2 gene across patients and provide evidence of the translational meaning of our in vitro results